Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Lewis C. Cantley

Lewis C. Cantley

Scientific Founder, Faeth Therapeutics; Discoverer of PI3K

Appears in 1 story

Notable Quotes

"The PI3K pathway is the most mutated pathway in cancer. But every time you block one node, the pathway finds a way around it." — Lewis Cantley, 2019

Stories

Multi-node PI3K inhibition reaches clinical testing

New Capabilities

Scientific advisor to combined company

Lewis Cantley discovered the PI3K enzyme in 1985. Four decades later, a combination therapy targeting multiple nodes of the pathway he uncovered just demonstrated an 80% response rate in endometrial cancer patients—triple the historical rate with chemotherapy alone. Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million to push this approach through pivotal trials.

Updated 2 hours ago